CHRONIC MYELOID LEUKEMIA (CML) Managing the Long and the Short of It
|
|
- Maryann Chase
- 6 years ago
- Views:
Transcription
1
2 CHRONIC MYELOID LEUKEMIA (CML) Managing the Long and the Short of It Jeffrey H Lipton PhD MD Princess Margaret Cancer Centre Professor of Medicine University of Toronto CAGPO Annual Conference St. John s, NFLD October 24, 2014
3 Disclosure Research Support/P.I. Employee Consultant Stockholder Speakers Bureau Scientific Advisory Board Other BMS, Novartis, Roche, Pfizer (Wyeth), Merck (Schering), Teva (ChemGenex), Ariad BMS, Novartis, Roche, Merck, Teva, Pfizer, Alexion, Ariad, CSL Behring BMS, Novartis, Roche. Pfizer, Teva, Alexion, Ariad, CSL Behring
4 Disclosure This presentation is assisted by unrestricted sponsorship by Pfizer Canada Inc Under the guidance of the Rx&D Code of Canada Content is determined by the speaker Any off label uses of drugs will be indicated
5 Ice Breaker Just by Show of Hands How many of you will be involved in the diagnosis of new malignancies versus managing patients already diagnosed? How many of you in this room treat or will be treating leukemias? How many of you in this room treat or will be treating CML? How many of you feel comfortable with the concept of targeted therapy?
6 Goals of this Presentation Gain an understanding of CML, the disease Understand the concept of targeted therapy Know the options for first line therapy in CML Learn the importance of monitoring disease and side effects of patients on therapy Understand the principles of when to switch therapy, ie second or third line What to do when targeted therapy does not appear to be working
7 What is chronic myeloid leukemia? Biology and Epidemiology
8
9
10
11 The Philadelphia Chromosome (Ph) BCR-ABL gene structure Chromosome 22 bcr 1 Chromosome abl p210bcr-abl p185bcr-abl Exons Introns CML Breakpoints ALL Breakpoints Nowell PC, Hungerford DA. Science. 1960;132: Forrest et al, 2008; Bakshi et al, 2008; Nowell and Hungerford. JNCI. 1960;25. Rowley 1973.
12
13
14
15 Diagnosis of CML
16
17
18
19 Choosing a Treatment Path
20 Pre History or what we did in the days before targeted therapy
21 A walk through history Arsenic Lissauer, 1865 Radiotherapy Pusey, 1902 Busulfan Galton, 1953 Hydroxyurea Fishbein et al, 1964 Autografting Buckner et al, 1974 Allogeneic BMT (SD) Doney et al, 1978 Interferon Talpaz et al, 1983 Allogeneic BMT (UD) Beatty et al, 1989 Donor Leukocytes Kolb et al, 1990
22 CML Milestones 1 st description of pts w/ CML features Philadelphia chromosome identified Translocation identified as 22q to distal end of 9 BCR-ABL Kinase activity characterized TKI efficacy against BCR-ABL characterized Arsenic RT Busulfan IFNa Allogeneic SCT Imatinib Nilotinib, Dasatinib Bosutinib, OM, 22 ponatinib
23 Proportion Surviving Improved Survival of Early Chronic Phase CML % Y ear T otal Dead Imatinib Y ears from Referral Quintas-Cardama et al. Mayo Clin Proc. 2006; 81:
24 Probability of Survival CML Survival After Allogeneic SCT (FHCRC) Chronic phase (n = 576) Accelerated phase (n = 125) Blast crisis/remission (n = 62) Blast crisis (n = 44) Yrs After Transplantation *Includes both matched related and unrelated donors. Patients receiving allografts at the Fred Hutchinson Cancer Research Center from 1995 to the present. Figure is courtesy of Dr. Ted Gooley.
25 PMH CML Transplant Results Zaretsky 2007 Zaretsky, BMT (2007)
26 What is Targeted Therapy? Just the facts ma am
27 WWII ENOLA GAY AND HIROSHIMA 1944 AKA Conventional Chemotherapy
28 US PRECISION BOMBING OF IMPERIAL GUARD BUILDING IRAQ 2003 AKA Targeted Therapy
29 Therapy of Newly Diagnosed Patients with CML
30 What are the goals of CML therapy? Basically: to keep people from progressing from chronic phase to advanced phase. People rarely die from CML in chronic phase Ideally: To reduce the tumor load or molecular level of bcr-abl to undetectable disease To be able to maintain this response off therapy Cynically: To keep people alive with CML, so they can die from something else
31 Imatinib Dasatinib Nilotinib Tyrosine Kinase Inhibitors Currently Available and Approved in Canada for First-Line Therapy* brand Gleevec (Novartis) generic Apotex already problems with back orders! generic Teva generic Cobalt, just approved brand Sprycel (BMS) brand Tasigna (Novartis) * Health Canada approval and provincial reimbursement are not synonymous
32 IRIS R A N D O M I Z E Imatinib n = 553 IFN-a + Ara-C n = (3%) 359 (65%) Crossover Discontinued study treatment 181 (33%) 364 (66%) 13 (2%) Hochhaus A. et al, Blood. 2007; 110, 11. Abstract 25. ASH 2007 Oral Presentation
33 % Responding Druker BJ, et al. N Engl J Med. 2006;355: Response with 1st-Line Imatinib at 60 Months % 85% 80% 84% 98% 92% 87% 70 69% 60 CHR 50 MCR 40 CCR CCR IM = 68% IFN/Ara-c = 7% Months since randomization to imatinib mesylate CCR = complete cytogenetic response.
34 Alive % OS on First-Line Imatinib (IRIS Study) Estimated overall survival at 8 years was 85% (93%, considering only CML-related deaths) Survival: deaths associated with CM L Overall Survival Months Since Randomization Deininger M, et al. ASH Annual Meeting Abstracts. 2009;114:1126.
35 With Event, % IRIS 8-Year Update Results: Annual Event Rates Imatinib Arm Event Loss of CHR, Loss of MCyR, AP/BC, Death during treatment AP/BC Estimated EFS at 8 years = 81% Year 1 progression to AP/BC and 2 non-cml related deaths occurred in year 8 Estimated rate of freedom from progression to AP/BC at 8 years = 92% Deininger, ASH 2009
36 % Alive Survival After Progression to AP/BP Median Survival 10.5 months Progressed = 34 Died = 23 Alive = Months Since Progression Saglio et al, 2011.
37 2nd Generation TKIs vs Imatinib Treatment-Naïve CP-CML ENESTnd N = centers 35 countries Primary Endpoint: MMR at 12 Months *Stratified by Sokal risk score. Follow-up 5 years DASISION N = centers 26 countries R A N D O M I Z E D Dasatinib 100 mg QD (N = 259) Imatinib 400 mg QD (N = 260) *Stratified by Hasford risk score. Follow-up 5 years Primary Endpoint: Confirmed CCyR at 12 Months 37
38 Patients With MR 4.5, % Second-Generation TKIs Produce Deeper MRs Compared With Imatinib Nilotinib 300 mg BID (n = 282) Nilotinib 400 mg BID (n = 281) Imatinib 400 mg QD (n = 283) Δ 6% to 10% By 1 Year a 11%, P < %, P < % By 4 Years a 40%, P < %, P =.0002 Δ 14% to 17% By 5 Years a 54%, P < %, P <.0001 Δ 21% to 23% Time Since Randomization, calendar years Rates of MR 4.5 by 5 years were consistently higher with nilotinib vs imatinib in patients with low, intermediate, or high Sokal risk scores a Cumulative response rates reported consider each year to consist of twelve 28-day cycles. Saglio G, et al. Blood. 2013;122(21) [abstract 92]. 23% 31% Data cutoff: May 22, 2013
39 Second-Generation TKIs Produce Deeper 60 MRs Compared With Imatinib P <.030 Dasatinib 100 mg QD n = 259 Imatinib 400 mg QD n = % With MR % 18% 23% 34% 21% 37% 30% 10 9% 12% 0 2% Months Cortes J, et al. Blood. 2013;122(21);[abstract 653].
40 MMR by 12 Months is Predictive of Undetectable BCR-ABL Transcript Levels Undetectable BCR-ABL, % MMR by 12 months (n = 24) No MMR by 12 months (n = 29) 72% P < Pre Years on imatinib 5% Branford S, et al. Clin Cancer Res. 2007;13:
41 Number of Patients, n Progression to AP/BC: Including Events After Discontinuation (ITT Analysis)* ENESTnd 3-Year Update P =.0496 HR = 0.5 [0.2, 1.0] P =.0076 HR = 0.3 [0.1, 0.8] % 2.1% 6.7% On Core Treatment and After Discontinuation Nilotinib 300 mg BID Nilotinib 400 mg BID Imatinib 400 mg QD Off treatment progression information was prospectively collected for all patients every 3 months after discontinuation In the IRIS study, cumulative progression rates in the first 3 years of therapy were approximately 6% on imatinib 1 * Progression to AP/BC or death following progression. 1. Hochhaus A, et al. Leukemia. 2009;23(6): Data cut-off: 27Jul Saglio G, et al. Blood. 2011;118(21): [abstract 452].
42 DASISION: First-Line Dasatinib vs. Imatinib in CML-CP. Progression to AP/BP 15 Dasatinib 100 mg QD Imatinib 400 mg QD Progressed to AP/BP (n) % 9 3.5% 0 No patient who achieved MMR progressed to accelerated or blast phase 2 patients who achieved CCyR progressed to accelerated or blast phase (1 with dasatinib, 1 with imatinib)
43 It is difficult comparing drugs and outcomes outside of direct randomizations where the same language is spoken! Jabbour and Lipton, 2013
44 Efficacy Data from Studies Using Second Generation Drugs First Line Jabbour and Lipton,
45 Importance of Achieving Deep Molecular Response Achievement of MMR is associated with Longer duration of CCyR 1-4 Higher rates of EFS 5 and PFS 6 Durable MMR is associated with improved PFS 7 Early, deep MR is associated with EFS, 5,8-10 PFS, 6,10,11 higher OS 11 and deeper MRs 12 MR 4.5 may predict survival better than CCyR 13 Deeper MR (MR 4 or MR 4.5 ) is a prerequisite for many treatment-free remission trials Iacobucci I, et al. Clin Cancer Res; 2006:12, Cortes J, et al. Clin Cancer Res. 2005;11: Paschka P, et al. Leukemia. 2003;17: Press RD, et al. Blood. 2006;107: Press RD, et. al. Clin Cancer Res. 2007;13: Hughes TP, et al. New Engl J Med. 2003;349: Kantarjian H, et al. Cancer. 2008;112: Müller MC, et al. Blood. 2008;112:129 [abstract 333]. 9. Osborn MP, et al. Blood. 2009;114: [abstract 1125]. 10. Marin D, et al. J Clin Oncol. 2012;30: Hanfstein B, et al. Leukemia. 2012;26(9): Branford S, et al. Clin Cancer Res. 2007;13: Hehlmann et al. J Clin Oncol Feb 10;32(5): Mahon FX, et al. Lancet Oncol. 2010;11(11): Rousselot P, et al. Blood. 2011;118(21) [abstract 3781]. 16. Matsuki E, et al. Blood. 2011;118(21) [abstract 3765]. 17. Ross M, et al. Haematologica. 2012;97(s1):74 [abstract 0189]. MR 4, molecular response 4-log reduction; MR 4.5, molecular response 4.5-log reduction.
46 So, you may ask, how do you choose which drug to use? Provincial or private payer guidelines and/or reimbursement may make this an easy choice A good initial history, physical and baseline bloodwork assessment may help define comorbidities which make one drug preferable over another Lifestyle review including shift work and eating habits may help define a preferable drug At diagnosis, there are no response/resistance criteria to help with the decision For many patients, it will be like
47 More drugs means more choices!
48 Monitoring
49 When we talk about monitoring It is usually assumed that we are dealing with response to therapy Although this is in part correct, it is also important to check for Compliance Side effects that may influence compliance Additional medications that may have been changed or added by other treaters
50 Decisions based on monitoring visits include Whether to continue with current management Whether to change management because of failed response Whether to change management because of side effects (INTOLERANCE) Dosing change Drug change Whether discontinuation of therapy on protocol for those with deepest responses
51 Therapy Efficacy Monitoring
52 Monitoring CML Hematological response (HR) Measure of blood count and differentials Cytogenetic response (CyR) Chromosome banding analysis of bone cell metaphases Molecular Response Measurement of BCR-ABL1 transcript levels Maslak P. ASH Image Bank. 2008; Copyright American Society of Hematology Quintas-Cardama A, et al. Leukemia. 2007;21: Image reprinted by permission from Macmillian Publishers Ltd. Copyright Baccarani M, et al. J Clin Oncol. 200;27:
53 Defining Response Type of Response Definition CHR Complete Hematologic Response Normal differential, WBC, platelets ULN MCyR Major cytogenetic Response 0-35% Ph+ marrow metaphases CCyR Complete Cytogenetic Response 0% Ph+ marrow metaphases MMR Major Molecular Response BCR-ABL/ABL 0.1% (International Scale) CMR Complete Molecular Response Undetectable BCR-ABL (test of sensitivity 4.5 logs) 53
54 First-line Treatment Milestones Have Evolved The European LeukemiaNet (ELN) recommendations for optimal responses have shifted to deeper responses 3 to 6 months earlier in treatment Similarly, failure criteria occur 3 months earlier vs 2009 ELN recommendations 2009 ELN 2 ELN Definition of Optimal Response in Newly Diagnosed Patients 3 months 6 months 12 months Beyond 12 months 2013 ELN 3 BCR-ABL IS = 10% BCR-ABL IS = 1% a Platelet count < /L, white blood cells (WBC) < /L, differential count without immature granulocytes, and < 5% basophils; b 36% to 65% Ph+ metaphases; c 1% to 35% Ph+ metaphases; d No Ph+ metaphases; e BCR-ABL IS 0.1%; f BCR-ABL to ABL (or other housekeeping gene) ratio 0.1%. BCR-ABL IS = 0.1% BCR-ABL IS = % 1. Baccarani M, et al. J Clin Oncol. 2009;27(35): Baccarani M, et al. Blood. 2013;122(6): BCR-ABL IS, BCR-ABL transcripts measured on the International Scale; CCyR, complete cytogenetic response; mcyr, minor cytogenetic response; PCyR, partial cytogenetic response.
55 BCR-ABL1 transcripts (log 10 ) Correlation Between Response and Disease Burden: Molecular Response Number of leukaemic cells Haematologic CHR (<1-log reduction) CCyR (2-log reduction) MMR (3-log reduction) Cytogenetic RQ-PCR log reduction 10 6 Diagnosis Time Baccarani M, et al. Blood. 2006;108: ; Radich JP. Blood. 2009;114: RT-qPCR, reverse transcription - quantitative polymerase chain reaction
56 The Treatment Milestones in Ph+ CML Continue to Evolve: Earlier and Deeper Today Goal of Therapy CHR 1 MCyR 1,2 MMR 3 Deeper molecular responses 4 Leukemic Reduction 3,a 10% 1-log 1% 2-log 0.1% IS 3-log Leukemic Burden % IS 4.5-log 1. Cortes JE, et al. Am J Med. 1996;100(5): Rosti G, et al. Semin Hematol. 2003;40(2 suppl 2): Baccarani M, et al. Blood. 2006;108(6): Saglio G, et al. Blood. 2013;122(21):[abstract 92]. 5.Radich JP. Clin Lymphoma Myeloma. 2009;9(suppl 4):S391-S Hughes TP, et al. Blood. 2010;116(19): Press RD, et al. Clin Cancer Res. 2007;13(20): MR 4.5 and beyond 5-7 CHR, complete hematologic response; CML, chronic myelogenous leukemia; MCyR, major cytogenetic response; MMR, major molecular response; MR 4.5, molecular response with 4.5-log reduction below baseline; Ph+, Philadelphia chromosome positive.
57 Standardization of RQ-PCR for BCR-ABL: The International Scale (IS) Local Assay BCR - ABL / ABL BCR - ABL / BCR BCR - ABL / GUS 100% 10% International Scale IRIS standardised baseline 35% Ph+ Different primers/probes TaqMan LightCycler Rotorgene Others 1% 0.1% 0.01% 0.001% MMR = MR 3 MR 4 MR 5 0% Ph+ (CCyR) Hughes T, et al. Blood. 2006;108:28-37.
58 BCR-ABL/ABL % IS Apparent Fluctuating Levels of Residual Disease MMR MR Months
59 Definitions of Deep Molecular Deep MRs are defined as: 1 MR 4.0 : >4.0-log reduction in BCR-ABL1 transcripts either (i) detectable disease with <0.01 % BCR ABL1 IS or (ii) undetectable disease with >10,000 ABL1 or >24,000 GUSB transcripts Response MR 4.5 : >4.5-log reduction in BCR-ABL1 transcripts either (i) detectable disease with <0.0032% BCR ABL1 IS or (ii) undetectable disease in cdna with >32,000 ABL1 or >77,000 GUSB transcripts CHR (<1-log) CCyR (2-log) MMR (3-log) MR 4.0 MR log reduction 1.Baccarani et al. Blood. 2013;122: Cross NCP, et al. Leukemia. 2012;26: IS, international scale.
60 What to do when you expect that the drug is not working Determine if this is an intolerance issue or a resistance issue If intolerance, see if the dosing, schedule, use of co-meds can be changed If resistance, first determine if it is a compliance issue If not compliance, check Mutation status Evidence of clonal progression
61 Microelectronic Monitoring System (MEMS 6 Trackcap) Records the time of opening the container Most reliable method of measuring adherence Our patients: not told about the chip Marin et al, Blood 2008
62 Marin et al, Blood 2008
63 Probability of MMR Six-year probability of MMR according to the measured adherence rate p < Adherence >90%, n= Adherence 90%, n= Marin et al, Blood 2008 Months from start of imatinib therapy
64 The 2013 ELN Recommendations Support Switching Treatments in Patients With Treatment Failures Optimal Responses 1 3 mo Ph+ 35% and/or BCR-ABL 10% 6 mo Ph+ 0% and/or BCR-ABL < 1% 12 mo BCR-ABL 0.1% (MMR) At any time BCR-ABL 0.1% (MMR) Failures 1 3 mo Ph+ > 95% 6 mo Ph+ > 35% and/or BCR-ABL > 10% 12 mo BCR-ABL > 1% At any time Loss of CCyR; CCA/Ph+; confirmed loss of MMR a ; mutations Per ELN recommendations, BCR-ABL > 10% at 6 months is considered treatment failure and the patient should receive another treatment 1. Baccarani M, et al. Blood. 2013;122(6): CCA, clonal chromosomal abnormalities.
65 Impact of 6 month versus 3 month assessment on outcome of molecular response Kim et al 2014
66 Tyrosine Kinase Sensitivity in CML bcr-abl Mutations BMS Canada, unpublished
67 Tyrosine Kinase Inhibitors Currently Available and Approved in Canada for Salvage Therapy* Imatinib brand Gleevec (Novartis) generic Apotex! generic Teva generic Cobalt, just approved Dasatinib brand Sprycel (BMS) Nilotinib brand Tasigna (Novartis) Bosutinib brand Bosulif (Pfizer) * Health Canada approval and provincial reimbursement are not synonymous
68 % Dasatinib dose and schedule optimization in CP-CML Hematologic and cytogenetic response CHR MCyR CCyR mg QD 50 mg BID 140 mg QD 70 mg BID Hochhaus, ASH 2006
69 Proportion progression-free Dasatinib dose and schedule optimization in CP-CML Progression-free survival N No. progressed 100 mg QD mg BID mg QD mg BID Months Progression was defined as confirmed AP / BP, loss of CHR / MCyR, or increasing WBC count Hochhaus, ASH 2006
70 Without Progression, % Nilotinib - Phase II CML-CP Time to Progression 78% 64% Total = 321 Failed = 88 lll = Censored observations Months Since Start of Treatment Kantarjian, ASH 2007
71 Alive, % Nilotinib - Phase II CML-CP Survival 95% 91% Total = 321 Failed = 25 lll = Censored observations Kantarjian, ASH 2007 Months Since Start of Treatment
72 Probability of progression-free survival (%) Bosutinib Progression-free Survival Patients with any mutation CP 2L CP 3L ADV Time to progression/death (months) Mutation status CP 2L CP 3L ADV No mutation, n PFS rate at 1 year 92% (84.5% 95.6%) 80% (62.3% 90.2%) 43% (28.0% 57.5%) PFS rate at 2 years 86% (76.8% 91.3%) 80% (62.5% 90.2%) 34% (19.8% 48.9%) Any mutation, n PFS rate at 1 year 87% (76.2% 92.9%) 82% (63.7% 91.9%) 42% (28.1% 54.3%) PFS rate at 2 years 70% (57.3% 80.0%) 77% (56.2% 88.9%) 30% (17.7% 44.1%) CP, chronic phase chronic myeloid leukemia; 2L, second-line setting; 3L, third-line setting; ADV, advanced leukemia; PFS rates at 1 year (48 weeks) and 2 years (96 weeks) were based on Kaplan-Meier estimates. PFS, progression-free survival.
73 Probability of overall survival (%) Bosutinib Overall Survival Time to death (months) Patients with any mutation CP 2L CP 3L ADV Mutation status CP 2L CP 3L ADV No mutation, n OS rate at 1 year 97% (92.0% 98.8%) 93% (79.6% 97.7%) 65% (51.2% 76.2%) OS rate at 2 years 95% (89.0% 97.4%) 88% (72.5% 94.6%) 55% (40.4% 67.4%) Any mutation, n OS rate at 1 year 97% (90.0% 99.3%) 88% (72.5% 94.6%) 54% (41.3% 65.6%) OS rate at 2 years 82% (71.6% 89.4%) 79% (62.9% 89.2%) 46% (33.7% 58.0%) CP, chronic phase chronic myeloid leukemia; 2L, second-line setting; 3L, third-line setting; ADV, advanced leukemia; OS, overall survival. OS rates at 1 year (48 weeks) and 2 years (96 weeks) were based on Kaplan-Meier estimates.
74 BELA Trial: Bosutinib vs Imatinib Newly Diagnosed CML CP N = 502 R Bosutinib (500 mg QD), n = 250 Imatinib (400 QD), n = 252 Bosutinib, n = 250 Imatinib, n = months CCyR 56% 61% Cumulative CCyR 70% 81% 30-month MMR 45% 43% Cumulative MMR 61% 50% Progression to AP or BP 1.6% 5.2% Deaths 3.6% 5.2% Bosutinib had a higher incidence of GI toxicities and similar rates of myelosuppression compared to imatinib Reduction of BCR-ABL:ABL transcript to 10% at 3, 6, and 9 months were associated with higher rates of MMR and CCyR for both bosutinib and imatinib Gambacorti-Passerini C, et al. ASCO Meeting Abstracts. 2012;6512.
75 So how do you chose which drug to use in salvage? All the criteria for front line choice PLUS Directed by a mutation Directed by a side effect of the front line drug that may also be present with one of the salvage drug
76 Side Effects
77 Short Term Usually defined by the fact that they show up early, are often short lived or can be controlled with co-medications or changes in administration Are usually mild, ie grade 1 or 2 and although annoying, usually do not interfere with taking the drug
78 Drug and Short Term Side Effects Imatinib Rash, GI symptoms, MSK symptoms, edema, LFT abnormalities Dasatinib Rash, abdominal discomfort, headache Nilotinib Abdominal discomfort, pancreatic and LFT abnormalities, increased blood sugars and cholesterol Bosutinib Abdominal discomfort, diarrhea, LFT abnormalities
79 Potential Long-Term Drug Toxicities and Choice of TKI
80 BACKGROUND 1 Significant side effects or adverse events that occur when a patient is started on a TKI can either be managed with simple options, dose changes or co-medications Occasionally a drug will have to be switched because of a severe or intractable AE Patients who get out a few years, tolerate their therapy and respond may be on their TKI for many years
81 BACKGROUND 2 Some patients will be eligible for discontinuing their therapy because of deep durable responses, the definition of which is still not standardized It is likely though that many patients will be on lifelong therapy and dealing with issues that may be associated with their particular therapy will need to be addressed
82 Fundamental Realities Generally, no specific medication is absolutely contraindicated, resistance aside Some TKIs in some people may pose a greater potential risk of side effects Choice of a TKI that has the potential for issues will therefore involve a risk/benefit analysis after getting full medical information, followed by a detailed discussion with the patient and more aggressive monitoring and possible intervention
83 Caveat I will look at problems that can continue to show up in patients even after years of therapy and at new late problems I will look at the red flags that have been raised with TKIs I will not comment on whether the definitions of these issues are correct or appropriate or whether studies were designed to collect this data accurately I am not going to talk about cause and effect, or patient risk going into treatment, just the observed associations that are likely significant and need thought and monitoring
84 Imatinib
85 Long Term AE s with Imatinib In general, after more than a decade of usage, there have been no new long term adverse advents identified with imatinib Persistence of low grade chronic side effects such as edema, gastrointestinal sensitivity and musculoskeletal problems continue Imatinib has continued to be a safe long term tolerated medication in those individuals who are responding
86 Dasatinib
87 Long Term AE s with Dasatinib Pleural Effusions Pleural effusions, likely of an immunologic etiology, and possibly of an innocent bystander effect, continue to be an issue Effusions can occur for the first time or recur years after starting the drug and constant vigilance is necessary Dose reductions do not necessarily prevent recurrence
88 Long Term AE s with Dasatinib The exact incidence of PAH with dasatinib is not known but is probably under reported Despite the severity, it is not a common side effect Symptoms including dyspnea in the absence of pleural effusions or evidence of congestive heart failure need to be investigated Confirmation of PAH requires aggressive work up with echocardiography and probably heart catheterization Early intervention with discontinuation of dasatinib is essential as PAH is essentially not reversible significantly in this scenario
89 Occurrence of PAH in Patients Treated With Dasatinib: Key Learnings Approximately 42,000 patients with CML or Ph+ ALL have received dasatinib worldwide 70 cases of PH identified PAH cases confirmed by RHC and dasatinib was considered the most likely cause In most cases, patients had received previous treatment for CML PAH cases primarily identified via postmarketing surveillance In total, 2866 patients have been treated with dasatinib in clinical trials 8,9 3 cases of PAH determined by RHC have been identified 1 case in CA (START-A: 2 nd -line dasatinib in CML-AP) 2 cases in CA (2 nd -line dasatinib in CML-BP, CML-AP, Ph+ ALL) 1. Rasheed W, et al. Leuk Res 2009;33: ; 2. Mattei D, et al. Bone Marrow Transplant 2009;43: ; 3. Dumitrescu D, et al. Eur Respir J 2011;38: ; 4. Hennigs JK, et al. BMC Pulm Med 2011;11:30; 5. Orlandi EM, et al. Leuk Res 2012;36:e4-6; 6. Philibert L, et al. Fundam Clin Pharmacol 2011;25(suppl 1); 7. Montani D, et al. Circulation 2012;125: ; 8. Bristol-Myers Squibb. Sprycel (dasatinib) EMEA summary of product characteristics, revised December 2010; 9. Bristol-Myers Squibb. Sprycel (dasatinib) US prescribing information, revised October 2011
90 Nilotinib
91 Newly Acquired Alteration of Glucose Metabolism in the ENESTnd Study Glycemic Status by 3 Years in Patients With Normal Glycemic Status at Baseline Nilotinib 300 mg BID Nilotinib 400 mg BID Imatinib 400 mg QD (n = 91) a (n = 92) (n = 88) a Pre-diab. b Diabetes c Prediab. b Diabetes c Prediab. b Diabetes c Patients with newly acquired alteration of glucose metabolism, n (%) 34 (37.4) 16 (17.6) 43 (46.7) 16 (17.4) 34 (38.6) 1 (1.1) HbA 1c altered, 25 n (%) d (27.2) 4 (4.4) 42 (43.8) 6 (6.3) 27 (29.0) 0 a Patients with normal glycemic status at baseline who were evaluable for change in glycemic status by 3 years. b Patients with prediabetes by 3 years had either FGL 1.1 to < 1.26 g/l or HbA1c 5.7% to < 6.5%, or met both criteria. c Patients with diabetes by 3 years had either FGL > 1.26 g/l or HbA1c > 6.5%, or met both criteria. d Patients who met the HbA1c criterion for prediabetes or diabetes, respectively. Adapted from Rea D, et al: Blood 2012; 120(21):[abstract 1686].
92 Cardiac and Vascular Events by 4 Years in the ENESTnd Study (All Grades) Patients With an Event, n (%) Nilotinib 300 mg BID n = 279 Nilotinib 400 mg BID n = 277 Imatinib 400 mg QD n = 280 IHD 11 (3.9) 14 (5.1) 3 (1.1) PAOD 4 (1.4) 5 (1.8) 0 (0) IHD, ischemic heart disease; PAOD, peripheral arterial occlusive disease. Data cutoff: July Adapted from Kantarjian HM, et al: Blood 2012; 120(21):[abstract 1676].
93 Bosutinib
94 Long Term CV AE s with Bosutinib (Salvage and BELA Studies) Median (range) tx duration, mo Cardiac TEAEs (any grade), % Cardiac arrhythmia Pooled 2L/3L/4L 1L BOS* BOS * BOS (n=818) (n=570) * (n=248) ( ) ( ) IM (n=251) 33.3 ( ) Coronary artery disorder Heart failure Myocardial disorder Pericardial disorder Vascular hypertensive disorder * 500 or 400 mg/d starting dose Gambacorti-Passerini et, ASCO 2014
95 Tyrosine Kinase Inhibitors and Other Medications Currently Not Approved in Canada for Salvage Therapy Ponatinib brand Iclusig (Ariad) Omacetaxine brand Synribo (Teva)
96 When is a TKI not the treatment of choice for salvage? Persistent hematological toxicity Clonal progression Some clonal abnormalities in Ph-neg cells Unusual mutation such as t315i if ponatinib not available Uncontrolled heart failure
97 Survival Probability Allo SCT for CML in the Imatinib Era Elective, n = 19, 3-yr survival: 88% Imatinib failure in 1 CP, n = 37, 3-yr survival: 94% Advanced phase, n = 28, 3-yr survival: 59% Mos After Transplantation Saussele S, et al. Blood. 2010;115:
98 What does a physician taking care of a patient with CML need to remember and need to do? Issues for the GPO
99 Most important things to remember Newly diagnosed chronic phase CML patients have a life expectancy virtually the same as age matched controls Monitoring the patient and the disease are equally important Since patients will likely not die from CML, making sure that they do not die from other diseases that are treatable is equally important
100 Necessary Information At starting therapy A good patient history, physical and baseline laboratory assessment is necessary to sort out best choice of drug given disease status and if choice is an option During monitoring Careful assessment in conjunction with primary physician and/or other specialist to identify, modify, or treat co-morbidities or side effects Monitoring must include more than just disease response assessments
101 Drug Choice Deciding on what TKI to use depends on a number of issues: Drug availability This varies from jurisdiction to jurisdiction Disease status First line or salvage Previous responses Presence of kinase mutations Patient status Co-morbidities Previous adverse events on therapy
102 Must knows if you are to manage CML Know the drugs, especially the potential side effects Know the disease, especially the aspects of response or resistance Know the milestones what to look for and when Know the options for management at any time point, including the non-tki options Know a mentor someone you can learn from and someone who is available to answer questions
103 The Future - Maybe
104 Survival Without Molecular Relapse Duration of Therapy: Is TKI Therapy Forever? Do patients need to stay on TKI therapy forever? STIM trial RFS after discontinuation of imatinib, N = mo: 45%, 12 mo: 43%, 24 mo: 41% Pts at Risk, n Mahon FX, et al. Lancet Oncol. 2010;11(11):
Chronic Myeloid Leukemia A Disease of Young at Heart but Not of Body
Chronic Myeloid Leukemia A Disease of Young at Heart but Not of Body Jeffrey H Lipton, PhD MD FRCPC Staff Physician, Princess Margaret Cancer Centre Professor of Medicine University of Toronto POGO November,
More informationCML: Living with a Chronic Disease
CML: Living with a Chronic Disease Jorge Cortes, MD Chief, CML and AML Sections Department of Leukemia M. D. Anderson Cancer Center Houston, Texas Survival in Early Chronic Phase CML TKI Interferon Chemotherapy
More informationCML and Future Perspective. Hani Al-Hashmi, MD
CML and Future Perspective Hani Al-Hashmi, MD Objectives Learning from CML history Outcome of interest to clinician Patient and community interest!! Learning from CML history Survival Probability (All
More informationELN Recommendations on treatment choice and response. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy
ELN Recommendations on treatment choice and response Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy ELN 2013 Response to Front-line Treatment Baseline 3 months 6 months OPTIMAL
More informationRole of Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed CML. GIUSEPPE SAGLIO, MD University of Torino, Italy
Role of Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed CML GIUSEPPE SAGLIO, MD University of Torino, Italy Outcome in 282 Patients Treated with Imatinib First Line in Hammersmith Hospital
More information2 nd Generation TKI Frontline Therapy in CML
2 nd Generation TKI Frontline Therapy in CML Elias Jabbour, M.D. April 212 New York Frontline Therapy of CML in 212 - imatinib 4 mg daily - nilotinib 3 mg BID - dasatinib 1 mg daily Second / third line
More informationHOW I TREAT CML. 4. KONGRES HEMATOLOGOV IN TRANSFUZIOLOGOV SLOVENIJE Z MEDNARODNO UDELEŽBO Terme Olimia, Podčetrtek,
HOW I TREAT CML 4. KONGRES HEMATOLOGOV IN TRANSFUZIOLOGOV SLOVENIJE Z MEDNARODNO UDELEŽBO Terme Olimia, Podčetrtek, 12. - 14. april, 2012 Gianantonio Rosti Dpt of Hematology and Oncological Sciences S.
More informationChronic Myeloid Leukaemia
Chronic Myeloid Leukaemia Molecular Response: What is really important? Jeff Szer The Royal Melbourne Hospital PROBABILITY, % PROBABILITY OF SURVIVAL AFTER MYELOABLATIVE TRANSPLANTS FOR CML IN CHRONIC
More informationGuidelines and real World: Management of CML in chronic and advanced phases. Carolina Pavlovsky. FUNDALEU May 2017 Frankfurt
Guidelines and real World: Management of CML in chronic and advanced phases Carolina Pavlovsky. FUNDALEU 26-28 May 217 Frankfurt Some Issues in CML 217 First Line treatment: Imatinib vs 2nd generation
More informationHow I treat high risck CML
Torino, September 14, 2018 How I treat high risck CML Patrizia Pregno Hematology Dept. Citta della Salute e della Scienza Torino Disclosures Advisory Board: Novartis, Pfizer, Incyte Speaker Honoraria:
More informationThe BCR-ABL1 fusion. Epidemiology. At the center of advances in hematology and molecular medicine
At the center of advances in hematology and molecular medicine Philadelphia chromosome-positive chronic myeloid leukemia Robert E. Richard MD PhD rrichard@uw.edu robert.richard@va.gov Philadelphia chromosome
More informationMolecular monitoring of CML patients
EHA, Education Session, CML Stockholm, 14 June 2013 Molecular monitoring of CML patients Martin C. Müller Medical Faculty Mannheim Ruprecht-Karls-University Heidelberg Mannheim, Germany Disclosures Research
More informationDoes Generic Imatinib Change the Treatment Approach in CML?
Does Generic Imatinib Change the Treatment Approach in CML? Jerald P. Radich, MD Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance NCCN.org For Clinicians NCCN.org/patients For Patients
More informationThe concept of TFR (Treatment Free Remission) in CML
The concept of TFR (Treatment Free Remission) in CML Giuseppe Saglio University of Turin, Italy What can we expect today on long-term therapy with TKIs in CML? German CML study IV Relative and overall
More informationContemporary and Future Approaches in CML. Emory Meeting; Sea Island August 2014 Hagop Kantarjian, M.D.
Contemporary and Future Approaches in CML Emory Meeting; Sea Island August 2014 Hagop Kantarjian, M.D. 1 CML. Historical vs. Modern Perspective Parameter Historical Modern Course Fatal Indolent Prognosis
More information2nd generation TKIs to first line therapy
New Horizons 2011 Newly diagnosed CML moving 2nd generation TKIs to first line therapy Gianantonio Rosti Dept. Of Hematology and Oncology St. Orsola-Malpighi University Hospital Bologna (Italy) GIMEMA
More informationStopping TKI s in CML- Are we There Yet? Joseph O. Moore, MD Duke Cancer Institute
Stopping TKI s in CML- Are we There Yet? Joseph O. Moore, MD Duke Cancer Institute Natural History of CML Accumulation of immature myeloid cells New cytogenetic changes Chronic Phase Accelerated Phase
More informationA 34-year old women came because of abdominal discomfort. Vital sign was stable. Spleen tip was palpable.
1 Case 1 A 34-year old women came because of abdominal discomfort. Vital sign was stable. Spleen tip was palpable. CBC and bone marrow aspiration and biopsy were done. Chromosome study showed she had t(9;22)
More informationEUROPEAN LEUKEMIANET RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA
EUROPEAN LEUKEMIANET RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA SAN DIEGO, 11 DECEMBER 2011 AMSTERDAM, 14 JUNE 2012 BALTIMORE, 20 SEPTEMBER 2012 ATLANTA, 6 DECEMBER 2012 ELN, CML Panel Jane Apperley
More informationLa terapia della LMC: è possibile guarire senza trapianto? Fabrizio Pane
La terapia della LMC: è possibile guarire senza trapianto? Fabrizio Pane What could be the concept of Cure in CML? Sustained DMR with or without TKI therapy And 100% CML-related survival And QoL comparable
More informationContemporary and Future Approaches in Management of CML. Disclosures
Winship Cancer Institute of Emory University Contemporary and Future Approaches in Management of CML Hagop Kantarjian, MD Chairman and Professor, Department of Leukemia University of Texas M. D. Anderson
More informationIRIS 8-Year Update. Management of TKI Resistance Will KD mutations matter? Sustained CCyR on study. 37% Unacceptable Outcome 17% 53% 15%
Management of TKI Resistance Will KD mutations matter? IRIS 8-Year Update 17% 53% 5% 15% 37% Unacceptable Outcome No CCyR Lost CCyR CCyR Other 3% 7% Safety Lost-regained CCyR Sustained CCyR on study Deininger
More informationCML David L Porter, MD University of Pennsylvania Medical Center Abramson Cancer Center CML Current treatment options for CML
1 CML 2012 LLS Jan 26, 2012 David L Porter, MD University of Pennsylvania Medical Center Abramson Cancer Center CML 2012 Current treatment options for CML patients Emerging therapies for CML treatment
More informationI nuovi guariti? La malattia minima residua nella leucemia mieloide cronica. Fabrizio Pane
I nuovi guariti? La malattia minima residua nella leucemia mieloide cronica Fabrizio Pane What could be the concept of Cure in CML? Sustained DMR with or without TKI therapy And 100% CML-related survival
More informationRESEARCH ARTICLE. Introduction. Methods Wiley Periodicals, Inc.
BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase AJH Dennis (Dong Hwan) Kim, 1 * Nada Hamad,
More informationWhat is the optimal management strategy for younger CP-CML patients with matched, related donors who fail to achieve CCyR
What is the optimal management strategy for younger CP-CML patients with matched, related donors who fail to achieve CCyR after 18 months of imatinib? Second generation TKIs as a bridge to allogeneic SCT
More informationCML: Yesterday, Today and Tomorrow. Jorge Cortes, MD Chief CML Section Department of Leukemia The University of Texas, M.D. Anderson Cancer Center
CML: Yesterday, Today and Tomorrow Jorge Cortes, MD Chief CML Section Department of Leukemia The University of Texas, M.D. Anderson Cancer Center Five Years of Signal Transduction Inhibition The Beginning
More informationCML Update 2016 Arthur 2016
CML Update 2016 Chronic Myeloid Leukemia Splenomegaly CML (3 phase disease) Increased white cells Malignant proliferation of myeloid white cells Initially mature cells a) chronic phase of disease Evolution
More informationWhat is New in CML in Hagop Kantarjian, M.D. February 2011
What is New in CML in 2011 Hagop Kantarjian, M.D. February 2011 1 CML. Historical vs. Modern Perspective Parameter Historical Modern Course Fatal Indolent Prognosis Poor Excellent 10-yr survival 10% 84-90%
More informationDati sulla sospensione della terapia
Leucemia Mieloide Cronica Dati sulla sospensione della terapia Gianantonio Rosti, Bologna BCR-ABL Loading in CML Patients 100% 10% 1% MMR MR 4 MR 4.5 STIM study design N=100 Start Imatinib CMR Sustained
More informationImatinib & Ponatinib. Two ends of the spectrum in 2016s reality
Imatinib & Ponatinib Two ends of the spectrum in 2016s reality CML 2016 Benefits & risks Steve O Brien CML Horizons, May 2016 Disclosures Research funding, participation in company trial, speaker, consultant,
More informationLow doses of tyrosine kinase inhibitors in CML
CML Horizons Conference Warsaw 4-6 May 2018 Low doses of tyrosine kinase inhibitors in CML Delphine Rea, MD, PhD Pôle Hématologie Oncologie Radiothérapie INSERM UMR-1160 Centre Hospitalo-Universitaire
More informationC Longer follow up on IRIS data
hronic Myeloid Leukemia Drs. Rena Buckstein, Mervat Mahrous & Eugenia Piliotis with input from Dr. J. Lipton (PMH) Updated August 2008* Updates: C Longer follow up on IRIS data Guidelines for monitoring
More informationOxford Style Debate on STOPPING Treatment.
Oxford Style Debate on STOPPING Treatment. This house believes that there are good reasons NOT to stop CML treatment. It should be done within clinical trials, OR only in expert centers where frequent,
More information10 YEARS EXPERIENCE OF TYROSINE KINASE INHIBITOR THERAPY FOR CML IN OXFORD
10 YEARS EXPERIENCE OF TYROSINE KINASE INHIBITOR THERAPY FOR CML IN OXFORD Dalia Khan 1, Noemi Roy 1, Vasha Bari 1, Grant Vallance 1, Helene Dreau 1, Timothy Littlewood 1, Andrew Peniket 1, Paresh Vyas
More informationNew drugs in first-line therapy
New drugs in first-line therapy Gianantonio Rosti Dept of Hematology and Oncology Seràgnoli, Bologna University (Italy) GIMEMA (Gruppo Italiano Malattie Ematologiche dell Adulto) CML WORKING PARTY IRIS
More informationNEW DRUGS IN HEMATOLOGY
NEW DRUGS IN HEMATOLOGY BOLOGNA, 15-17 April 2013 TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKEMIA MICHELE BACCARANI michele.baccarani@unibo.it Historic Development of CML Therapy Palliative Therapy
More informationSESSION III: Chronic myeloid leukemia PONATINIB. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy
SESSION III: Chronic myeloid leukemia PONATINIB Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy Ponatinib A Pan-BCR-ABL Inhibitor Rationally designed inhibitor of BCR- ABL
More informationDose reduction. What do we know and how we do it in clinical practice. Andreas Hochhaus
Dose reduction. What do we know and how we do it in clinical practice. Andreas Hochhaus Hadera I Oct 2018 Front-line Randomized Trials in CML-CP Trial Drugs References IRIS IM 400 vs IFN/AraC TOPS IM
More informationHistory of CML Treatment
History of CML Treatment Eduardo Olavarria No conflict of interest Lisbon, 20th March 2018 #EBMT18 www.ebmt.or What is CML? The mystery of chronic myeloid leukaemia Chronic myeloid leukaemia Often diagnosed
More informationJuan Luis Steegmann Hospital de la Princesa. Madrid. JL Steegmann
Juan Luis Steegmann Hospital de la Princesa. Madrid. Juan Luis Steegmann Hospital de la Princesa. Madrid No rush,at least in Chronic Phase Blast Phase*: SCT asap, after restablishing CP with TKI Accelerated
More informationTreatment free remission in CML: from the concept to practice. François-Xavier Mahon. Cancer Center Bordeaux Université Bordeaux, France
Treatment free remission in CML: from the concept to practice François-Xavier Mahon Cancer Center Bordeaux Université Bordeaux, France CML is a model 1960 1970 1980 1990 2000 2010 Philadelphia chromosome
More informationWelcome and Introductions
Living with Chronic Myeloid Leukemia Welcome and Introductions Living with Chronic Myeloid Leukemia Living with Chronic Myeloid Leukemia (CML) Neil P. Shah, MD, PhD Edward S. Ageno Distinguished Professor
More informationBMS Satellite Symposium
ICKSH 2018 BMS Satellite Symposium Emerging Trends in CML Management CHAIRMAN The Head of Catholic Hematology Hospital The Director of the Catholic Leukemia Research Institute at the Catholic University
More informationChronic myeloid leukemia (CML) Warunsuda Sripakdee, BCOP,BCP Prince of Songkla University
Chronic myeloid leukemia (CML) 1 Warunsuda Sripakdee, BCOP,BCP Prince of Songkla University Hematologic malignancies CML ALL AML 2 CML CD34+ results from an acquired mutation that affects hematopoietic
More informationState of the Art Therapy and Monitoring of CML Hagop Kantarjian, M.D. Grand Rounds UT Southwestern. October 28, 2010
State of the Art Therapy and Monitoring of CML - 2010 Hagop Kantarjian, M.D. Grand Rounds UT Southwestern October 28, 2010 1 CML. Historical vs. Modern Perspective Parameter Historical Modern Course Fatal
More informationAccepted Manuscript. Improving Outcomes in Chronic Myeloid Leukemia Over Time in the Era of Tyrosine Kinase Inhibitors. Pradnya Chopade, Luke P.
Accepted Manuscript Improving Outcomes in Chronic Myeloid Leukemia Over Time in the Era of Tyrosine Kinase Inhibitors Pradnya Chopade, Luke P. Akard PII: S2152-2650(18)30343-4 DOI: 10.1016/j.clml.2018.06.029
More informationCML HORIZONS 101 AND CML 101
CML HORIZONS 101 AND CML 101 by Pat Garcia-Gonzalez, USA May 1, 2015 Barcelona, Spain Goals of this Session Everything you ever wanted to know and were afraid of asking Help you navigate the conference
More informationCML: definition. CML epidemiology. CML diagnosis. CML: peripheralbloodsmear. Cytogenetic abnormality of CML
MolecularDiagnostic.be Third Scientific Meeting Molecular Diagnostics.be t(9;22) CML: definition Management of CML patients treated with TKI: the place of molecular monitoring Antwerp, December 13 th 11
More informationMilestones and Monitoring
Curr Hematol Malig Rep (2015) 10:167 172 DOI 10.1007/s11899-015-0258-1 CHRONIC MYELOID LEUKEMIAS (E JABBOUR, SECTION EDITOR) Milestones and Monitoring Alessandro Morotti 1 & Carmen Fava 1 & Giuseppe Saglio
More informationStopping Treatment in CML and dose reduction in clinical practice: Can we do it safely? YES WE CAN!
Stopping Treatment in CML and dose reduction in clinical practice: Can we do it safely? YES WE CAN! Dragana Milojković The Hammersmith Hospital, London, UK Leukemic burden Current Aim of TKI therapy Molecular
More informationManagement of CML in blast crisis. Lymphoma Tumor Board November 27, 2015
Management of CML in blast crisis Lymphoma Tumor Board November 27, 2015 Chronic Phase CML - 2. Peter Maslak, ASH Image Bank 2011; 2011-2455 Copyright 2011 American Society of Hematology. Copyright restrictions
More informationStarting & stopping therapy in Chronic Myeloid Leukemia: What more is needed? Richard A. Larson, MD University of Chicago March 2019
Starting & stopping therapy in Chronic Myeloid Leukemia: What more is needed? Richard A. Larson, MD University of Chicago March 2019 Disclosures Richard A. Larson, MD Research funding to the University
More informationState of the Art Therapy and Monitoring of CML Hagop Kantarjian, M.D. Grand Rounds Hackensack, New Jersey. September 22, 2010
State of the Art Therapy and Monitoring of CML - 2010 Hagop Kantarjian, M.D. Grand Rounds Hackensack, ew Jersey September 22, 2010 1 CML. Historical vs. Modern Perspective Parameter Historical Modern Course
More informationVenice Meeting Highlights: Key lessons. Conclusions Michele Baccarani Rüdiger Hehlmann
Venice Meeting Highlights: Key lessons Conclusions Michele Baccarani Rüdiger Hehlmann CML therapy in the imatinib era CML prognosis has improved dramatically Cellular and molecular biology studies help
More informationIs there a best TKI for chronic phase CML?
MANAGING TYPICAL AND ATYPICAL CHRONIC MYELOID LEUKEMIA Is there a best TKI for chronic phase CML? Richard A. Larson 1 1 Section of Hematology/Oncology, Department of Medicine, and Comprehensive Cancer
More informationBlast Phase Chronic Myelogenous Leukemia
Blast Phase Chronic Myelogenous Leukemia Benjamin Powers, MD; and Suman Kambhampati, MD The dramatic improvement in survival with tyrosine kinase inhibitors has not been demonstrated in the advanced blast
More informationMRD in CML (BCR-ABL1)
MRD in CML (BCR-ABL1) Moleculaire Biologie en Cytometrie cursus Barbara Denys LAbo Hematologie UZ Gent 6 mei 2011 2008 Universitair Ziekenhuis Gent 1 Myeloproliferative Neoplasms o WHO classification 2008:
More informationCML TREATMENT GUIDELINES
CML TREATMENT GUIDELINES INITIAL INVESTIGATION Propose enrolment in the CML Registry of the CML-MPN Quebec Research Group. Medical history : Question for cardio-respiratory disorders, diabetes, pancreatitis,
More informationMolecular Detection of BCR/ABL1 for the Diagnosis and Monitoring of CML
Molecular Detection of BCR/ABL1 for the Diagnosis and Monitoring of CML Imran Mirza, MD, MS, FRCPC Pathology & Laboratory Medicine Institute Sheikh Khalifa Medical City, Abu Dhabi, UAE. imirza@skmc.ae
More informationStopping treatment how much we understand about mechanisms to stop successfully today, and where are the limits? Andreas Hochhaus
Stopping treatment how much we understand about mechanisms to stop successfully today, and where are the limits? Andreas Hochhaus Frankfurt I 27.5.2017 Aims of CML Therapy Leukemia cells >10 12 CHR 10
More informationThe speaker has no financial relationships with a commercial interest to disclose and no conflicts of interest to resolve.
Hana Safah MD Professor of Medicine Tulane University School of Medicine Director of the SCT program, Tulane Medical Center The speaker has no financial relationships with a commercial interest to disclose
More informationImplementation of Management Guidelines
Implementation of Management Guidelines For Chronic Myeloid Leukemia Perspectives in the United States David Rizzieri, MD; and Joseph O. Moore, MD ABSTRACT Clinical practice guidelines are developed to
More informationWhat is New in CML Jorge Cortes, MD Chief, CML and AML Sections Department of Leukemia MD Anderson Cancer Center Houston, Texas
What is New in CML 2018 Jorge Cortes, MD Chief, CML and AML Sections Department of Leukemia MD Anderson Cancer Center Houston, Texas Final Results CML-IV Molecular Response with Imatinib 1538 pts newly
More informationEvaluating Cost-Effectiveness in Later-line Chronic Myeloid Leukemia (CML): Ponatinib in the Third-Line Treatment of CML in Canada
Evaluating Cost-Effectiveness in Later-line Chronic Myeloid Leukemia (CML): Ponatinib in the Third-Line Treatment of CML in Canada Jeffrey H. Lipton, Sergio Iannazzo, Silvia Chiroli, Lisa McGarry 06 CADTH
More informationCML Clinical Case Scenario
CML Clinical Case Scenario Neil Shah, MD, PhD Edward S. Ageno Distinguished Professor in Hematology/Oncology Leader, Hematopoietic Malignancies Program Helen Diller Family Comprehensive Cancer Center at
More informationDiscontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: What s Stopping us from Stopping?
Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: What s Stopping us from Stopping? David Pham, PharmD PGY2 Hematology/Oncology Pharmacy Resident South Texas VA Health Care System
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Bosutinib (Bosulif) for Chronic Myelogenous Leukemia April 21, 2015
pan-canadian Oncology Drug Review Final Clinical Guidance Report Bosutinib (Bosulif) for Chronic Myelogenous Leukemia April 21, 2015 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationNEW DRUGS IN HEMATOLOGY Bologna, 9-11 May 2016 CHRONIC MYELOID LEUKEMIA STATUS OF THE ART OF TREATMENT.
NEW DRUGS IN HEMATOLOGY Bologna, 9-11 May 2016 CHRONIC MYELOID LEUKEMIA STATUS OF THE ART OF TREATMENT Michele.baccarani@unibo.it Michele BACCARANI, MD Professor of Hematology at the Universities of Trieste,
More informationWhen to change therapy? Andreas Hochhaus Universitätsklinikum Jena, Germany
When to change therapy? Andreas Hochhaus Universitätsklinikum Jena, Germany Chromosome 22 Chromosome 9 e1 1b m-bcr M-bcr e1 e2 b1 b5 5 3 BCR ABL 5 3 1a a2 a3 μ -bcr e19 a11 e1a2 b2a2 b3a2 e19a2 p190 bcr-abl
More informationCML 301 SOME INTRODUCTION INTO CML, CML SCIENCE, DRUG DEVELOPMENT AND INFORMATION RESOURCES. by Sarunas Narbutas Jan Geissler.
CML 301 SOME INTRODUCTION INTO CML, CML SCIENCE, DRUG DEVELOPMENT AND INFORMATION RESOURCES by Sarunas Narbutas Jan Geissler 4 May 2018 CML 101 / BASICS: UNDERSTANDING THE DISCUSSIONS IN CML SESSIONS What
More informationOutlook CML 2016: What is being done on the way to cure
New Horizons 2011 Outlook CML 2016: What is being done on the way to cure Gianantonio Rosti Dept. Of Hematology and Oncology St. Orsola-Malpighi University Hospital Bologna (Italy) GIMEMA CML Working Party
More informationMeasuring Response to BCR-ABL Inhibitors in Chronic Myeloid Leukemia
Review Article Measuring Response to BCR-ABL Inhibitors in Chronic Myeloid Leukemia Jerald P. Radich, MD In patients with chronic myeloid leukemia (CML), the hallmark Philadelphia chromosome is the marker
More informationWhat Can We Expect from Imatinib? CML Case Presentation. Presenter Disclosure Information. CML Case Presentation (cont)? Session 2: 8:15 AM - 9:00 AM
Welcome to Master Class for Oncologists Session 2: 8:15 AM - 9: AM Miami, FL December 18, 29 Chronic Myelocytic Leukemia: Imatinib and Beyond Speaker: Daniel J. DeAngelo, MD, PhD Dana-Farber Cancer Institute
More informationCurrent Monitoring for CML: Goals and. Jorge Cortes, MD Chief, CML & AML Section Department of Leukemia MD Anderson Cancer Center
Current Monitoring for CML: Goals and Principles Jorge Cortes, MD Chief, CML & AML Section Department of Leukemia MD Anderson Cancer Center Survival in Early Chronic Phase CML MDACC 2009 The Philadelphia
More informationThe development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients
J Cancer Res Clin Oncol (2013) 139:1971 1984 DOI 10.1007/s00432-013-1488-z REVIEW The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in
More informationDAVID S. SNYDER, M.D.
CML UPDATE 2019 DAVID S. SNYDER, M.D. MARCH 21,2019 Click to edit Master Presentation Date Disclosures I do not have anything to disclose 2001 2016 Loss in expectation of life of patients with chronic
More informationDiagnosis and Management of Chronic Myeloid Leukaemia
Diagnosis and Management of Chronic Myeloid Leukaemia Dr Simon Watt Dr Katherine O Neill Dr Fiona Dignan Written July 2017 Prof Tim Somervaille Review July 2019 1 Table of Contents 1.0 Introduction 3 2.0
More informationCML UPDATE 2018 DAVID S. SNYDER, M.D. MARCH
CML UPDATE 2018 DAVID S. SNYDER, M.D. MARCH 15, 2018 Click to edit Master Presentation Date DISCLOSURES I have nothing to disclose 2001 2016 Loss in expectation of life of patients with chronic myeloid
More informationExecutive summary Overview
Executive summary Overview In this appraisal, we have demonstrated that dasatinib is clinically more effective, as well as more cost effective, than imatinib, the current standard of care. In the pivotal
More informationSecond-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase
Critical Reviews in Oncology/Hematology 82 (2012) 159 170 Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase Gianantonio Rosti, Fausto Castagnetti,
More informationShould nilotinib replace imatinib as first line treatment of chronic myeloid leukemia in chronic phase (CML-CP)?
Should nilotinib replace imatinib as first line treatment of chronic myeloid leukemia in chronic phase (CML-CP)? http://test.metromomsblog.org/wp-content/uploads/2010/02/tortoise-and-the-hare.jpg D. Van
More informationRecent advances in the path toward the cure for chronic myeloid leukemia
VOLUME 46 ㆍ NUMBER 3 ㆍ September 2011 THE KOREAN JOURNAL OF HEMATOLOGY REVIEW ARTICLE Recent advances in the path toward the cure for chronic myeloid leukemia Dong-Wook Kim Department of Hematology, Seoul
More informationDecision Making in CML 2010
Decision Making in CML 2010 Imatinib is the standard treatment for chronic myeloid leukaemia (CML), but approximately 25% of patients are resistant or non-responsive to imatinib. 1 While physicians have
More informationPractical Guidance for the Management of CML in 2016
Practical Guidance for the Management of CML in 2016 Neil Shah, MD, PhD Edward S. Ageno Distinguished Professor in Hematology/Oncology Leader, Hematopoietic Malignancies Program Helen Diller Family Comprehensive
More informationPatient With Chronic Myeloid Leukemia in Complete Cytogenetic Response: What Does It Mean, and What Does One Do Next?
VOLUME 32 NUMBER 5 FEBRUARY 10 2014 JOURNAL OF CLINICAL ONCOLOGY ONCOLOGY GRAND ROUNDS Patient With Chronic Myeloid Leukemia in Complete Cytogenetic Response: What Does It Mean, and What Does One Do Next?
More informationOriginal Study. Abstract
Original Study The Effectiveness of Tyrosine Kinase Inhibitors and Molecular Monitoring Patterns in Newly Diagnosed Patients With Chronic Myeloid Leukemia in the Community Setting Nicholas J. Di Bella,
More informationNew Anti Leukemic treatments deserve a Cardioncology approach. Guido Gini AOU «Ospedali Riuniti» Università Politecnica delle Marche Ancona
New Anti Leukemic treatments deserve a Cardioncology approach Guido Gini AOU «Ospedali Riuniti» Università Politecnica delle Marche Ancona CML Is Linked to a Single Cytogenetic Abnormality: The Philadelphia
More informationPonatinib Withdrawal Update
Hello. This is Dr. Stuart Goldberg from the Leukemia Division at the John Theurer Cancer Center at Hackensack University Medical Center in Hackensack, New Jersey. I am speaking on behalf of ManagingCML.com
More informationGreater Manchester and Cheshire Cancer Network Chronic Myeloid Leukaemia v3 2012
Greater Manchester and Cheshire Cancer Network Chronic Myeloid Leukaemia v3 2012 Dr Simon Watt Dr Shiva Natarajan 1.0 Introduction The landscape in chronic myeloid leukaemia (CML) has changed dramatically
More informationAllogeneic SCT for. 1st TKI. Vienna Austria. Dr. Eduardo Olavarría Complejo Hospitalario de Navarra
The International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) Berlin, Germany September 8-11, 2011 Vienna Austria Allogeneic SCT for CML Allogeneic after failure
More informationStudy Design and Endpoints
Complete Molecular Response (CMR) Rate With Nilotinib in Patients With CML-CP Without CMR After 2 Years on Imatinib: Preliminary Results From the Randomized ENESTcmr Trial Timothy P. Hughes, Jeffrey H.
More informationMolecular pathogenesis of CML: Recent insights
Napoli 24 gennaio 2012 Molecular pathogenesis of CML: Recent insights Giuseppe Saglio University of Turin CML Biology CML Clinical practice MILESTONES IN MOLECULAR BIOLOGY OF CML 1960 - Nowell P.C. & Hungerford
More informationHull and East Yorkshire and North Lincolnshire NHS Trusts Haematology Multidisciplinary Team Guideline and Pathway. Chronic Myeloid Leukaemia
Hull and East Yorkshire and North Lincolnshire NHS Trusts Haematology Multidisciplinary Team Guideline and Pathway Chronic Myeloid Leukaemia 1 BACKGROUND The Hull and North Lincolnshire Haematology Multidisciplinary
More informationMolecular monitoring in CML and the prospects for treatment-free remissions
MANAGING TYPICAL AND ATYPICAL CHRONIC MYELOID LEUKEMIA Molecular monitoring in CML and the prospects for treatment-free remissions Michael W. Deininger 1,2 1 Huntsman Cancer Institute, The University of
More informationChronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring
Received: 13 December 2017 Accepted: 17 December 2017 DOI: 10.1002/ajh.25011 ANNUAL CLINICAL UPDATES IN HEMATOLOGICAL MALIGNANCIES Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring
More informationPost ASH Actualités LMC
Post ASH 2014 - Actualités LMC Actualités de première ligne LMC PC ENESTnd (6 ans) Dasision (5 ans) EPIC Spirit France (5 ans) Spirit 2 UK (5 ans) ENESTnd: Mise à jour à 6 ans Design = 846 ults with wly
More information9/26/2018. Learning Objectives
ADVANCES IN CHRONIC MYELOID LEUKEMIA Alison Wakoff Loren, MD, MSCE Associate Professor of Medicine Director, Blood & Marrow Transplantation Vice Chair, Faculty Development Department of Medicine Perelman
More informationForm 2012 R3.0: Chronic Myelogenous Leukemia (CML) Pre-Infusion Data
Form 2012 R3.0: Chronic Myelogeus Leukemia (CML) Pre-Infusion Data Key Fields Sequence Number: Date Received: - - CIBMTR Center Number: CIBMTR Research ID: Event date: - - HCT type: (check all that apply)
More informationNCCP Chemotherapy Protocol. Bosutinib Monotherapy
Bosutinib Monotherapy INDICATIONS FOR USE: INDICATION Treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous
More information